Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 16 of 736 for:    Area Under Curve AND Bioavailability

Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01512459
Recruitment Status : Completed
First Posted : January 19, 2012
Last Update Posted : January 19, 2012
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
The objective of this study was to compare the relative bioavailability of Venlafaxine MR Capsules 150 mg with Effexor XR Capsules 150 mg under Fed conditions in healthy adult human subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Venlafaxine Phase 1

Detailed Description:
An open labeL balanced, randomized, two-treatment. two-period, two-sequence, single dose,crossover, evaluation of relative bioavailability of Venlafaxine 150 mg (as the HCl salt)MR capsules of Dr. Reddy's comparing with that of Effexor XR (containing Venlafaxine 150 mg (as the HCl salt)capsules of wyeth Laboratories, Philadelphia, PA, USA in healthy human subjects under fed conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Balanced, Randomized, Two-treatment, Two-sequence Two-period, Single Dose Sprinkled on Apple Sauce, Crossover and Relative Bioavailability Study in Healthy Adult, Human Subjects Under Fed Conditions
Study Start Date : May 2006
Actual Primary Completion Date : May 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malnutrition

Arm Intervention/treatment
Experimental: Venlafaxine MR Capsules 150
Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
Drug: Venlafaxine
Venlafaxine MR Capsules 150 mg
Other Name: Effexor XR

Active Comparator: Effexor XR 150 mg Capsules
Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
Drug: Venlafaxine
Venlafaxine MR Capsules 150 mg
Other Name: Effexor XR

Primary Outcome Measures :
  1. Area Under Curve (AUC) [ Time Frame: predose, 1.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 24.00, 36.00, 48.00 and 72.00 hours post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

  • Subjects who will provide written informed consent.
  • Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg.
  • Having a Body mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2
  • Subjects must be of normal health as determined by medical history and physical examination performed within 21days prior to the commencement of the study.
  • Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance.
  • Have normal ECG, X-ray and vital signs.
  • Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidence by written informed consent.

Exclusion Criteria:

  • Subjects incapable of understanding the informed consent.
  • Subjects who have:

    • Systolic blood pressure less than 90 mm of Hg and more than 140 .mm of Hg
    • Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator.
    • Pulse rate below 50/min and above 100/min.
  • History of hypersensitivity or idiosyncratic reaction to Venlafaxine or any other related drugs.
  • Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal .function.
  • Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study.
  • Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and until the completion of the study.
  • Subjects who have taken over the counter or prescribed medications for during the last 7 days from the date of study.
  • Subjects who have taken enzyme modifying drugs or any systemic medication within the past 30 days prior to start of clinical study
  • History of any psychiatric illness, which may impair the ability to provide written, informed consent.
  • Subjects with clinically significant abnormal values of laboratory parameters.
  • Subjects who have participated in any other clinical investigation using experimental drug or had bled more than 330 mL in the past 90 days before the date of start of study.
  • Subjects with positive screen for drugs of abuse and alcohol.
  • Any subject in whom Venlafaxine is contraindicated for medical reasons.
  • Any subject with recent history of surgery
  • A history of difficulty in donating blood.
  • A positive test result for HIV antibody and/or syphilis
  • A recent history of alcoholism (< 2 years) or of moderate (180 ml/day) alcohol use, or consumption of alcohol within 48 hr prior to receiving Investigational Product.
  • Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study will not be allowed to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01512459

Layout table for location information
Bioserve Clinical Research (P) Ltd
Balanagar, Hyderabad, India, 500 037
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Layout table for investigator information
Principal Investigator: Mohanlal Siva Prasad Sayana, Dr. Bioserve Clinical Research (P) Ltd

Layout table for additonal information
Responsible Party: Dr. Reddy's Laboratories Limited Identifier: NCT01512459    
Other Study ID Numbers: 610/06
First Posted: January 19, 2012    Key Record Dates
Last Update Posted: January 19, 2012
Last Verified: January 2012
Keywords provided by Dr. Reddy's Laboratories Limited:
two way crossover
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Venlafaxine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs